BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 27043173)

  • 1. Discovery of small-molecule nonpeptide antagonists of nociceptin/orphanin FQ receptor: The studies of design, synthesis, and structure-activity relationships for (4-arylpiperidine substituted-methyl)-[bicyclic (hetero)cycloalkanobenzene] derivatives.
    Hayashi S; Ohashi K; Mihara S; Nakata E; Emoto C; Ohta A
    Eur J Med Chem; 2016 May; 114():345-64. PubMed ID: 27043173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
    Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
    Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 1-(β-amino substituted-β-alanyl)-N,N-dimethylindoline-2-carboxamides as novel nonpeptide antagonists of nociceptin/orphanin FQ receptor: efficient design, synthesis, and structure-activity relationship studies.
    Hayashi S; Ohashi K; Nakata E; Emoto C
    Eur J Med Chem; 2012 Sep; 55():228-42. PubMed ID: 22898529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of nociceptin/orphanin FQ receptors, a novel opioid receptor family, in the midbrain periaqueductal gray.
    Chiou LC; Fan SH; Chuang KC; Liao YY; Lee SZ
    Ann N Y Acad Sci; 2004 Oct; 1025():398-403. PubMed ID: 15542742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential of Nociceptin/Orphanin FQ Peptide Analogs for Drug Development.
    Wtorek K; Janecka A
    Chem Biodivers; 2021 Jan; 18(1):e2000871. PubMed ID: 33351271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic.
    Thompson AA; Liu W; Chun E; Katritch V; Wu H; Vardy E; Huang XP; Trapella C; Guerrini R; Calo G; Roth BL; Cherezov V; Stevens RC
    Nature; 2012 May; 485(7398):395-9. PubMed ID: 22596163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.
    Zaveri NT; Jiang F; Olsen C; Polgar WE; Toll L
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3308-13. PubMed ID: 23623415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonpeptide/peptide chimeric ligands for the nociceptin/orphanin FQ receptor: design, synthesis and in vitro pharmacological activity.
    Guerrini R; Carra' G; Calo' G; Trapella C; Marzola E; Rizzi D; Regoli D; Salvadori S
    J Pept Res; 2004 Jun; 63(6):477-84. PubMed ID: 15175020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies.
    Spagnolo B; Carrà G; Fantin M; Fischetti C; Hebbes C; McDonald J; Barnes TA; Rizzi A; Trapella C; Fanton G; Morari M; Lambert DG; Regoli D; Calò G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):961-7. PubMed ID: 17329552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential In Vitro Pharmacological Profiles of Structurally Diverse Nociceptin Receptor Agonists in Activating G Protein and Beta-Arrestin Signaling at the Human Nociceptin Opioid Receptor.
    Lu JJ; Polgar WE; Mann A; Dasgupta P; Schulz S; Zaveri NT
    Mol Pharmacol; 2021 Jul; 100(1):7-18. PubMed ID: 33958480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel non-peptide nociceptin/orphanin FQ receptor agonist, 1-[1-(1-Methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole: design, synthesis, and structure-activity relationship of oral receptor occupancy in the brain for orally potent antianxiety drug.
    Hayashi S; Hirao A; Imai A; Nakamura H; Murata Y; Ohashi K; Nakata E
    J Med Chem; 2009 Feb; 52(3):610-25. PubMed ID: 19125610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptors.
    Zaveri NT; Journigan VB; Polgar WE
    ACS Chem Neurosci; 2015 Apr; 6(4):646-57. PubMed ID: 25635572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity relationships.
    Hayashi S; Nakata E; Morita A; Mizuno K; Yamamura K; Kato A; Ohashi K
    Bioorg Med Chem; 2010 Nov; 18(21):7675-99. PubMed ID: 20875743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1-Benzyl-N-[3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl]pyrrolidine-2-carboxamide (Compound 24) antagonizes NOP receptor-mediated potassium channel activation in rat periaqueductal gray slices.
    Liao YY; Trapella C; Chiou LC
    Eur J Pharmacol; 2009 Mar; 606(1-3):84-9. PubMed ID: 19374842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole: integrated drug-design and structure-activity relationships for orally potent, metabolically stable and potential-risk reduced novel non-peptide nociceptin/orphanin FQ receptor agonist as antianxiety drug.
    Hayashi S; Hirao A; Nakamura H; Yamamura K; Mizuno K; Yamashita H
    Chem Biol Drug Des; 2009 Oct; 74(4):369-81. PubMed ID: 19691471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor.
    Calo G; Guerrini R; Rizzi A; Salvadori S; Burmeister M; Kapusta DR; Lambert DG; Regoli D
    CNS Drug Rev; 2005; 11(2):97-112. PubMed ID: 16007234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ro 64-6198 [(1S,3aS)-8-(2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one] acts differently from nociceptin/orphanin FQ in rat periaqueductal gray slices.
    Chiou LC; Chuang KC; Wichmann J; Adam G
    J Pharmacol Exp Ther; 2004 Nov; 311(2):645-51. PubMed ID: 15254141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations.
    Ferrari F; Cerlesi MC; Malfacini D; Asth L; Gavioli EC; Journigan BV; Kamakolanu UG; Meyer ME; Yasuda D; Polgar WE; Rizzi A; Guerrini R; Ruzza C; Zaveri NT; Calo G
    Eur J Pharmacol; 2016 Dec; 793():1-13. PubMed ID: 27780725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor.
    Calo G; Rizzi A; Rizzi D; Bigoni R; Guerrini R; Marzola G; Marti M; McDonald J; Morari M; Lambert DG; Salvadori S; Regoli D
    Br J Pharmacol; 2002 May; 136(2):303-11. PubMed ID: 12010780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-Based SAR in the Design of Selective or Bifunctional Nociceptin (NOP) Receptor Agonists.
    Meyer ME; Doshi A; Yasuda D; Zaveri NT
    AAPS J; 2021 May; 23(3):68. PubMed ID: 33974173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.